Chiglitazar Sodium/Metformin Hydrochloride

西格列他钠/盐酸二甲双胍

Report date: 2026/04/07 20:00:20

Base Information

Drug NameChiglitazar Sodium/Metformin Hydrochloride
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonistsPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor delta agonists +[4] 
TargetsPeroxisome proliferator-activated receptor αPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor delta +[4] 
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Chiglitazar SodiumMetformin Hydrochloride
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Chipscreen Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Chipscreen Biosciences Co LtdChipscreen Biosciences Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A